Novartis halts CAR-T trials after patient deaths
Novartis stops eight trials of CAR-T rap-cel in autoimmune diseases after three deaths, with BMS also halting studies of zola-cel as a precaution.
White House signs pricing deals with nine more pharmas
Nine mid-sized pharmas have signed up for the Trump administration's Most-Favoured Nation (MFN) pricing deals, pledging almost $20bn in investments.
ESC26: Can Arrowhead pierce Ionis' triglyceride armour?
Arrowhead Pharma is squaring up to rival Ionis in the severe hypertriglyceridaemia (sHTG) market, drawing on phase 3 data at ESC 2026.
ESC26: AZ's relaxin agonist shows promise in heart failure
An oral relaxin agonist developed by AstraZeneca, codenamed AZD5462, has been shown to improve cardiac function in patients with heart failure.
FDA clears Takeda, Protagonist's first-in-class PV drug
Takeda and Protagonist's hepcidin mimetic rusfertide is the first hepcidin mimetic to be approved by the FDA for blood cancer polycythaemia vera.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
World Novel Drug Discovery Summit South Korea
Korea’s First Industry Forum Driving Best-in-Class Discovery for Next-Generation Modalities
2nd World-RNA Based Therapeutics & Vaccines Summit South Kor...
Korea’s Forum to Advance mRNA, CircRNA & saRNA Medicines for Clinical & Commercial Readiness
AI, Forecasting, Insights and Analytics for Smarter Decision...
Learn from case studies, expert-led panels, roundtable discussions, and interactive workshops on Gen AI-powered forecasting
30th Portfolio Decision-Making & Prioritisation for Pharma
Pharmaceutical portfolio decision-making is facing structural pressure.
R&D Governance, Controlling and Innovation for Pharma
The Marcus Evans R&D Governance, Controlling, and Innovation for Pharma conference will take place at the Crowne Plaza - Frankfurt Congress Hotel